ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,381.35
0.00%
Dow Jones
39,387.76
0.85%
Gold vs US Dollar
2,357.84
0.47%
Brent Oil
84.255
0.36%
Bitcoin
62,876.08
-0.27%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. CASI Pharmaceuticals Inc (CASI)

  7. CASI Pharmaceuticals Inc (CASI) News

CASI Pharmaceuticals (CASI)

CASI Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CASI
DateTimeSourceHeadlineSymbolCompany
08/04/202422:00PR Newswire (US)CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTASNASDAQ:CASICASI Pharmaceuticals Inc
28/03/202411:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
05/03/202412:00PR Newswire (US)CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In ChinaNASDAQ:CASICASI Pharmaceuticals Inc
16/02/202412:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINANASDAQ:CASICASI Pharmaceuticals Inc
14/11/202312:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATESNASDAQ:CASICASI Pharmaceuticals Inc
08/11/202312:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPANASDAQ:CASICASI Pharmaceuticals Inc
11/08/202312:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATESNASDAQ:CASICASI Pharmaceuticals Inc
01/08/202312:00PR Newswire (US)Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI PharmaceuticalsNASDAQ:CASICASI Pharmaceuticals Inc
20/07/202313:00PR Newswire (US)CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339NASDAQ:CASICASI Pharmaceuticals Inc
17/05/202312:35PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
26/04/202314:49PR Newswire (US)CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022NASDAQ:CASICASI Pharmaceuticals Inc
26/04/202313:27Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:CASICASI Pharmaceuticals Inc
26/04/202312:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
22/03/202310:04Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:CASICASI Pharmaceuticals Inc
21/03/202321:08Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:CASICASI Pharmaceuticals Inc
21/03/202320:51Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:CASICASI Pharmaceuticals Inc
21/03/202320:42Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CASICASI Pharmaceuticals Inc
21/03/202320:30PR Newswire (US)CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGERNASDAQ:CASICASI Pharmaceuticals Inc
09/02/202315:49Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CASICASI Pharmaceuticals Inc
01/02/202315:40Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CASICASI Pharmaceuticals Inc
31/01/202321:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CASICASI Pharmaceuticals Inc
06/01/202312:00PR Newswire (US)CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINANASDAQ:CASICASI Pharmaceuticals Inc
15/12/202212:00PR Newswire (US)CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATIONNASDAQ:CASICASI Pharmaceuticals Inc
16/11/202207:57TipRanksBTIG Sticks to Their Buy Rating for CASI Pharmaceuticals (CASI)NASDAQ:CASICASI Pharmaceuticals Inc
14/11/202221:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CASICASI Pharmaceuticals Inc
14/11/202212:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
28/09/202211:25TipRanksH.C. Wainwright Remains a Buy on CASI Pharmaceuticals (CASI)NASDAQ:CASICASI Pharmaceuticals Inc
23/09/202212:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEETNASDAQ:CASICASI Pharmaceuticals Inc
09/09/202221:03Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CASICASI Pharmaceuticals Inc
07/09/202212:00PR Newswire (US)CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINANASDAQ:CASICASI Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CASI

Your Recent History

LSE
CHLL
Chill Brands
LSE
TERN
Tern
LSE
SAR
Sareum
LSE
OPTI
Optibiotix Health
LSE
ITM
Itm Power
LSE
GKP
Gulf Keystone Petroleum
LSE
POLX
Polarean Imaging
LSE
SYME
Supply@me Capital
LSE
ENI
LSE
GDR
Genedrive
LSE
AGL
Angle
LSE
TYM
Tertiary Minerals
LSE
CLCO
Cloudcoco
LSE
PET
Petrel Resources
LSE
UPS
NYSE
SPCE
Virgin Galactic
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved